Pamela Stephenson - 22 Jul 2022 Form 4/A - Amendment Insider Report for ALBIREO PHARMA, INC.

Role: Chief Commercial Officer
Signature: /s/ Jason Duncan, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 22 Jul 2022
Net transactions value: -$2,615
Form type: 4/A - Amendment
Filing time: 09 Jan 2023, 17:41:23 UTC
Date Of Original Report: 25 Jul 2022
Previous filing: 28 Jun 2022
Next filing: 27 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALBO	Common Stock	Sale	$2,615	-106	-0.23%	$24.67	45,649	22 Jul 2022	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3	Represents 15,923 shares of common stock and 29,726 restricted stock units.

Remarks:

This amended Form 4 is being filed solely to correct the numbers of shares disclosed in column 5 of Table I and footnote 3, as the reporting person did not acquire 547 shares of common stock under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.